Halozyme Reports Second Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Halozyme Therapeutics (HALO) Tops Q2 EPS by 4c, Revenues Miss; Maintains FY19 Revenue Guidance Above Consensus
August 6, 2019 6:03 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $39.15 million versus the consensus estimate of $42.76 million.
Total Revenues Increase 11% to $39.1 Million Compared to $35.2 Million in Prior-year PeriodENHANZE® Partner Janssen Submits... More